Making Tomorrow’s
Cancer Treatment Better

We are Isofol

Isofol is a publicly listed biotechnology company in clinical phase that is developing the drug candidate arfolitixorin that aims to increase the efficacy of standard treatments for patients with severe forms of cancer.

Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.

Isofol’s shares are traded on Nasdaq Stockholm.